MorphoSys is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer. With the acquisition of Constellation Pharmaceuticals in July 2021, MorphoSys is building a significant presence in hematology-oncology. Being able to help patients and aiming to provide them with the best treatment available is the strongest motivation driving our more than 750 employees across Germany and the United States.